Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or
recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and
Maximum Tolerated Dose (MTD) To determine the pharmacokinetics (PK) of Oprozomib To explore
the anti-tumor activity of Oprozomib in this patient population including the overall
response rate (ORR), the duration of responses (DOR), the progression-free survival (PFS) and
time to progression (TTP) To define the pharmacodynamics (PDn) of Oprozomib.